Zacks Research Issues Optimistic Outlook for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities research analysts at Zacks Research lifted their Q4 2025 earnings per share estimates for Corcept Therapeutics in a research report issued on Tuesday, January 21st. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings per share of $0.54 for the quarter, up from their prior estimate of $0.53. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2026 earnings at $0.73 EPS, Q4 2026 earnings at $0.73 EPS and FY2026 earnings at $2.47 EPS.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.14. The firm had revenue of $182.55 million during the quarter, compared to the consensus estimate of $171.97 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.28 EPS.

CORT has been the subject of several other research reports. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. Truist Financial boosted their price objective on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a research note on Monday, September 30th. Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Finally, HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $65.25.

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT opened at $59.99 on Thursday. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The stock has a fifty day simple moving average of $55.16 and a two-hundred day simple moving average of $45.77. Corcept Therapeutics has a 1-year low of $20.84 and a 1-year high of $62.98. The firm has a market cap of $6.29 billion, a price-to-earnings ratio of 47.61 and a beta of 0.56.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Synergy Asset Management LLC boosted its position in Corcept Therapeutics by 131.3% during the fourth quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock valued at $22,369,000 after buying an additional 262,503 shares during the period. Pacer Advisors Inc. grew its holdings in Corcept Therapeutics by 18.3% in the 4th quarter. Pacer Advisors Inc. now owns 10,896 shares of the biotechnology company’s stock worth $549,000 after acquiring an additional 1,689 shares during the last quarter. KBC Group NV increased its position in shares of Corcept Therapeutics by 45.9% in the fourth quarter. KBC Group NV now owns 4,118 shares of the biotechnology company’s stock valued at $208,000 after acquiring an additional 1,296 shares during the period. Blue Trust Inc. raised its stake in shares of Corcept Therapeutics by 47.8% during the fourth quarter. Blue Trust Inc. now owns 17,225 shares of the biotechnology company’s stock valued at $797,000 after acquiring an additional 5,567 shares during the last quarter. Finally, Linden Thomas Advisory Services LLC boosted its holdings in shares of Corcept Therapeutics by 2.1% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 63,224 shares of the biotechnology company’s stock worth $3,186,000 after purchasing an additional 1,300 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Joseph Douglas Lyon sold 1,411 shares of the firm’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $56.72, for a total transaction of $80,031.92. Following the transaction, the insider now directly owns 8,494 shares of the company’s stock, valued at approximately $481,779.68. This trade represents a 14.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $50.54, for a total value of $111,188.00. The disclosure for this sale can be found here. Insiders sold a total of 38,011 shares of company stock valued at $1,951,268 in the last quarter. Corporate insiders own 20.50% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.